"We understand from Mylan NV's press release dated January 8, 2020,
that Mylan Pharmaceuticals has initiated a voluntary recall of three
lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to
detected trace amounts of impurity...," Solara Active Pharma Sciences
in a filing to BSE.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/solara-active-pharma-to-conduct-internal-probe-on-nizatidine-api-amid-mylan-recall/articleshow/73167327.cms
No comments:
Post a Comment